⚠ Evidence warning: Clinical trials or other evidence do not support the claim that silymarin is a useful add-on for hepatitis B or C symptoms and long-term liver protection. This page keeps it as a report of what people, websites or other media say.

Milk Thistle as Hepatitis Adjunctive Therapy

Hepatitis Adjunctive — scientific infographic poster

The story of milk thistle in chronic viral hepatitis is the most instructive case study in herbal medicine of how the evidence-base evolves as trial quality improves. From the 1980s through the early 2000s, milk thistle was widely promoted (especially in the United States) as a "treatment" for chronic hepatitis C based on small open-label trials showing reduced serum aminotransferases. The 2012 SyNCH trial — a properly powered U.S. National Institutes of Health-sponsored randomized placebo-controlled study of high-dose silymarin in interferon-failed hepatitis C virus (HCV) patients — produced unambiguously negative results: no benefit on serum alanine aminotransferase (ALT), on HCV RNA or on quality of life; the trial did not measure liver histology. At roughly the same time, the arrival of direct-acting antivirals (sofosbuvir, ledipasvir, glecaprevir, and successors) made hepatitis C virus definitively curable in over 95% of treated patients within 8-12 weeks. Milk thistle's role in hepatitis C virus has therefore been definitively recast: not a treatment of the virus, but an add-on that practitioners and patients describe using for symptomatic relief, fatigue, quality of life, and ongoing hepatic-cell-membrane stabilization during and after antiviral therapy. The hepatitis B virus (HBV) evidence is similar but smaller. This page walks through the trial history, the 2012 SyNCH inflection point, the modern hepatitis B virus/hepatitis C virus adjunct framework, and the silybin-phosphatidylcholine complex (IdB 1016), a form made to be better absorbed.


Table of Contents

  1. The Hepatitis C Virus Adjunct Question
  2. Early Open-Label and Small Randomized Controlled Trial Era (1980s-2000s)
  3. The HALT-C Lead-In Analysis (2008)
  4. The SyNCH Trial (2012) — The Inflection Point
  5. The Direct-Acting Antiviral (DAA) Era and the Modern Reframing
  6. Intravenous Silibinin in Hepatitis C Virus Salvage Therapy
  7. Hepatitis B Evidence Base
  8. Silybin-Phosphatidylcholine Complex (IdB 1016) and Absorption
  9. Standardized Silymarin and Quality Differences
  10. Doses Used in Trials and Described by Practitioners
  11. Symptom and Quality-of-Life Effects
  12. Cautions and Antiviral Drug Interactions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

The Hepatitis C Virus Adjunct Question

Hepatitis C virus (HCV) infection chronically affects an estimated 50-70 million people worldwide, including about 2.2 million United States adults during January 2017 to March 2020 in a U.S. Centers for Disease Control and Prevention (CDC) analysis, one third of them unaware of it, with substantially higher rates among people who are uninsured or poor (an earlier estimate was approximately 2.4 million). Untreated chronic hepatitis C virus leads to cirrhosis in 15-30% of patients over 20-30 years, with subsequent risk of hepatocellular carcinoma. The disease was, for decades, the principal indication for liver transplantation in developed countries.

The therapeutic landscape transformed completely between 2013 and 2018 with the introduction of direct-acting antivirals (DAAs) — combination regimens of sofosbuvir, ledipasvir, velpatasvir, glecaprevir, pibrentasvir, and others — that achieve sustained virologic response (cure) in over 95% of treated patients with 8-12 week oral courses. Hepatitis C virus is now considered curable for essentially anyone with access to treatment.

The question this page addresses is therefore not "does milk thistle treat hepatitis C virus" — we know the answer is no — but the more nuanced question: "what role, if any, does milk thistle play as an adjunct in hepatitis C virus patients?" The patient populations of interest are: (1) hepatitis C virus patients before they start DAA therapy (often a wait of weeks to months for prior-authorization or insurance approval), (2) hepatitis C virus patients during DAA therapy (potential symptomatic and hepatocellular support), (3) hepatitis C virus patients after DAA cure who have residual hepatic damage (cirrhosis, fibrosis, persistent alanine aminotransferase elevation), and (4) hepatitis C virus patients who cannot access or cannot tolerate DAAs.

Practitioners describe silymarin as an add-on for all four populations, based on its general hepatoprotective profile, but it does not affect the virus or change the trajectory of viral disease. The relevant outcomes are symptomatic and biochemical (alanine aminotransferase/aspartate aminotransferase (AST) reduction, fatigue, quality of life), not virologic.

Back to Table of Contents

Early Open-Label and Small Randomized Controlled Trial Era (1980s-2000s)

The early enthusiasm for milk thistle in chronic hepatitis came from a series of small, mostly open-label, mostly European studies in the 1980s and 1990s. Representative results:

These early results drove widespread off-label use of milk thistle for chronic hepatitis throughout the 1990s and 2000s, particularly in the United States where conventional hepatitis C virus therapy (interferon alpha plus ribavirin) had cure rates of only 30-50% with significant toxicity. Many hepatitis C virus patients turned to integrative medicine, and milk thistle was the most-recommended herbal supplement in that setting.

The pattern of evidence — small trials, soft endpoints (transaminases rather than viral load or fibrosis), open-label or inadequate blinding — was a classic setup for the larger, more rigorous trials of the late 2000s to deliver disappointing results.

Back to Table of Contents

The HALT-C Lead-In Analysis (2008)

The HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) trial was a large U.S. National Institutes of Health-sponsored multicenter trial of long-term low-dose interferon for prevention of cirrhosis progression in hepatitis C virus. As a substudy, the investigators (Seeff et al., Hepatology 2008) analyzed milk thistle use among the 1,145 enrolled hepatitis C virus patients.

Findings:

This was an early sign, on a large dataset, that the transaminase reduction seen in earlier small trials might not hold up. The HALT-C analysis was observational rather than randomized, but the size and quality of the dataset (1,145 patients with detailed clinical follow-up) made it influential. The investigators called for a well-designed prospective study, and SyNCH was the randomized trial that followed.

Back to Table of Contents

The SyNCH Trial (2012) — The Inflection Point

The SyNCH trial (Silymarin in non-alcoholic steatohepatitis (NASH) and C Hepatitis) was the long-awaited U.S. National Institutes of Health-funded (National Center for Complementary and Alternative Medicine), definitive randomized placebo-controlled trial of silymarin in chronic hepatitis C virus. Design: 154 patients with chronic hepatitis C virus and serum alanine aminotransferase of 65 U/L or greater who had failed prior interferon-based therapy, randomized to one of three arms for 24 weeks:

The silymarin preparation was a standardized dry extract of milk thistle fruits, approved as a prescription drug in several countries of Europe and Asia and the same kind of extract used in the European cirrhosis trials (a silymarin content of 89.4% has been quoted for it; the trial's main text does not state that figure). The 700 mg three-times-daily arm (2,100 mg/day) was the highest dose ever formally tested in hepatitis C virus.

Primary endpoint: serum alanine aminotransferase of 45 U/L or less (considered within the normal range), or less than 65 U/L provided this was at least a 50% decline from baseline, at week 24.

Results, published in JAMA (Fried MW et al., 2012):

The conclusion: "Higher than customary doses of silymarin did not significantly reduce serum ALT levels more than placebo in participants with chronic HCV infection unsuccessfully treated with interferon-based therapy."

This was the inflection point in the milk thistle / hepatitis C virus story. SyNCH was adequately powered, properly blinded, used a high-quality standardized preparation, and tested doses up to three times the standard dose. The trial did not find an effect because there was no effect to find at any dose tested.

The published response from the integrative medicine community focused on (1) the patient selection (interferon-failed patients with advanced disease) being unfavorable for any intervention, (2) the oral bioavailability limitation of standard silymarin (the phosphatidylcholine complex was not used), and (3) the choice of alanine aminotransferase reduction as the primary endpoint when fibrosis or HCV RNA might have been more relevant. These critiques have merit, but they do not rescue the underlying claim that silymarin treats hepatitis C virus.

Back to Table of Contents

The Direct-Acting Antiviral (DAA) Era and the Modern Reframing

The publication of SyNCH coincided with the emergence of direct-acting antiviral (DAA) therapy for hepatitis C virus. Telaprevir and boceprevir were approved in 2011 as first-generation DAAs added to interferon-based regimens; sofosbuvir (the first nucleotide polymerase inhibitor) was approved in late 2013 as the foundation of interferon-free regimens. By 2016, multiple all-oral 8-12 week DAA combinations were curing >95% of hepatitis C virus patients across all genotypes.

This made the SyNCH negative result moot in a practical sense. Hepatitis C virus is now a curable disease for any patient with access to DAA therapy. The question of what hepatitis C virus patients could take instead of DAAs no longer needs an answer for most patients.

Milk thistle's role in hepatitis C virus has therefore been reframed in three pragmatic ways:

  1. Pre-DAA hepatocellular support — for patients awaiting insurance approval, or with persistently elevated alanine aminotransferase and significant symptoms while awaiting treatment, practitioners describe silymarin at standard doses as possibly giving modest symptomatic and biochemical improvement during the wait. It does not affect the virus; the DAA course is what cures the infection.
  2. Concurrent with DAA therapy — some patients add milk thistle during their 8-12 week DAA course as general hepatoprotection. There is no evidence this helps DAA cure rates (which are already >95%), and interference has not been reported. Drug-interaction concerns are described as minimal at standard milk thistle doses: inhibition of cytochrome P450 3A4 (CYP3A4) is seen in the laboratory, while a 14-day study in nine healthy volunteers found no significant influence on CYP3A4/5 or three other P450 enzymes (Kawaguchi-Suzuki et al., 2014).
  3. Post-DAA cure with residual cirrhosis — patients cured of hepatitis C virus but left with cirrhosis remain at risk for hepatocellular carcinoma and decompensation. Practitioners describe silymarin as long-term hepatoprotection in this population, though no specific trials exist; the regimen they describe is standard 420 mg/day, indefinite duration, with periodic alanine aminotransferase and Child-Pugh assessment.

For the population without access to DAAs (uninsured patients in some U.S. settings, low-income countries with limited DAA access), milk thistle is used as a symptomatic add-on; the cure itself comes from DAAs, which people reach through patient-assistance programs, generic availability, or international procurement.

See our Hepatitis C page and Hepatitis overview page for the broader hepatitis C virus clinical picture.

Back to Table of Contents

Intravenous Silibinin in Hepatitis C Virus Salvage Therapy

A footnote to the hepatitis C virus / silymarin story: between 2008 and the DAA breakthrough, a small body of European literature explored intravenous silibinin as salvage therapy for hepatitis C virus patients with previous interferon failure, particularly in the post-transplant setting where hepatitis C virus recurrence is universal and rapid.

Ferenci and colleagues (Vienna 2008, Gastroenterology) gave intravenous (IV) silibinin at 5, 10, 15 or 20 mg/kg/day for 14 days to people who had not responded to pegylated interferon and ribavirin, adding those two drugs from day 8. The fall in HCV RNA depended on the dose. After 7 days of silibinin alone it was 2.11 log at 15 mg/kg and 3.02 log at 20 mg/kg; after 7 further days combined with pegylated interferon and ribavirin it was 3.69 and 4.85 log. HCV RNA became undetectable in 7 patients on 15 or 20 mg/kg at week 12. This was a much larger effect than ever observed with oral silymarin.

The mechanism was first hypothesized to involve direct inhibition of hepatitis C virus RNA-dependent RNA polymerase (NS5B) at the high tissue concentrations achievable with intravenous but not oral dosing. Later laboratory work changed that picture. Wagoner and colleagues (2010) found that silymarin, but not silibinin, inhibited the genotype 2a polymerase, and that silymarin's antiviral action appears to include blocking virus entry and transmission. Esser-Nobis and colleagues (2013) studied virus from a liver transplant recipient whose infection broke through on silibinin alone: it carried mutations in a different viral protein, nonstructural protein 4B (NS4B), and a mutation in the same protein gave partial resistance in cell culture, which points to a mechanism involving NS4B. The effect also differed by virus type: in that work silibinin strongly inhibited replication of genotypes 1a and 1b but barely affected genotype 2a.

The post-transplant reports are single cases. A 2011 letter (Beinhardt et al.) described intravenous silibinin alone preventing graft infection after liver transplantation in one patient with chronic hepatitis C. A 2012 report (Aghemo et al.) described the opposite in a woman with genotype 2a: after an initial fall, her HCV RNA rose steadily and silibinin was stopped after 15 days. The effect could also be transient — in the first Ferenci study, HCV RNA fell by 1.32 log on intravenous silibinin but increased again after the infusion period despite pegylated interferon and ribavirin.

This entire intravenous-silibinin-for-HCV literature was rendered obsolete by DAAs. Sofosbuvir achieved 4+ log reductions in HCV RNA at oral doses with vastly better tolerability than intravenous silibinin infusions. Intravenous silibinin is no longer used for hepatitis C virus in current practice but remains the standard antidote for amanita poisoning. The clinical-pharmacology data, however, established that silibinin at high tissue concentrations does have direct antiviral activity — just not at concentrations achievable by oral dosing.

Back to Table of Contents

Hepatitis B Evidence Base

The hepatitis B literature on milk thistle is smaller than the hepatitis C virus literature and considerably more heterogeneous. Hepatitis B virus is a different therapeutic challenge from hepatitis C virus because (1) most hepatitis B virus is suppressible but not curable with current antivirals (entecavir, tenofovir), (2) the principal goals of therapy are HBV DNA suppression and prevention of disease progression rather than cure, and (3) clearance of hepatitis B surface antigen (HBsAg) is the elusive functional-cure endpoint that current therapies rarely achieve.

Representative hepatitis B virus trials:

In summary, hepatitis B virus evidence for milk thistle is weaker than the hepatitis C virus evidence base and similarly does not support use as a primary or curative treatment. Practitioners describe adjunctive use during nucleoside analog therapy (entecavir, tenofovir); randomized evidence that it changes disease trajectory is lacking.

Back to Table of Contents

Silybin-Phosphatidylcholine Complex (IdB 1016) and Absorption

The persistent question raised by negative oral silymarin trials is whether higher tissue concentrations of silybin would have produced different results. Free silybin is poorly absorbed: a 2017 review calls its absorption efficiency "rather low" and cites an absolute oral bioavailability of 0.95% for pure silybin in rats, and in a 1990 study in healthy volunteers less than 3% of the dose was recovered in urine. It undergoes extensive conjugation to glucuronide and sulfate forms (which retain some but not all of the parent compound's activity). The elimination half-life is given as approximately 6 hours in the 2017 review and generally less than 4 hours in the 1990 study.

The silybin-phosphatidylcholine complex (IdB 1016) is a 1:2 molar complex. The phosphatidylcholine component is described as improving the lipid-membrane partitioning of silybin during intestinal absorption. In a 1990 study in 9 healthy volunteers, single doses equal to 360 mg of silybin gave higher plasma silybin levels at all sampling times with the complex than with silymarin; a figure of approximately 4.6-fold higher silybin plasma concentrations than equimolar standard silymarin is often quoted, though that study's abstract does not give it. The complex is also described as extending serum half-life modestly.

Pharmacokinetic figures quoted for the complex:

Clinical evidence for benefit of the complex beyond standard silymarin is mixed. The 2017 Wah Kheong non-alcoholic steatohepatitis trial (described on the Liver Protection page) gave silymarin 700 mg three times daily for 48 weeks; its abstract does not describe a phosphatidylcholine complex. The primary endpoint did not differ (32.7% versus 26.0%, P = .467), but significantly more patients on silymarin had reduced fibrosis on biopsy (22.4% versus 6.0%, P = .023) and on liver stiffness measurement (24.2% versus 2.3%, P = .002); the authors wrote that silymarin may reduce liver fibrosis but that this remains to be confirmed in a larger trial. Several small open-label hepatitis C virus pilots have suggested better transaminase responses with the complex than with equivalent oral silymarin.

On cost, the complex is roughly 3-5× the price of standard silymarin. Practitioners favor it on pharmacokinetic grounds for those who can afford it, and describe standard high-quality silymarin (80%-standardized) at higher doses (e.g., 700 mg twice daily instead of 140 mg three times daily) as reaching similar tissue exposure at lower cost.

Back to Table of Contents

Standardized Silymarin and Quality Differences

Essentially all rigorous clinical trials have been conducted with one original European pharmaceutical-grade standardized milk thistle extract. Its standardization specifications:

The clinical importance of standardization: generic supermarket milk thistle products may contain anywhere from 30% to 80% silymarin, may not specify silybin content separately, may have wide batch-to-batch variation, and frequently do not meet the European Pharmacopoeia monograph. A 175 mg "milk thistle" capsule from a generic brand may contain anywhere from 50 mg to 140 mg of actual silymarin — a nearly threefold range, with proportionally large variation in silybin content.

Where milk thistle is being used as a defined therapeutic intervention (chronic hepatitis adjunct, non-alcoholic fatty liver disease (NAFLD), post-acute liver injury recovery), the trial evidence comes from standardized 80%-silymarin preparations that meet European Pharmacopoeia specifications and other pharmaceutical-grade products. For general "liver support" without specific therapeutic claims, people also use lower-cost standardized products; unstandardized capsules carry the wide range in silymarin content described above.

Back to Table of Contents

Doses Used in Trials and Described by Practitioners

Trial doses on this page: 420 mg or 700 mg of silymarin three times daily for 24 weeks (SyNCH), 700 mg three times daily for 48 weeks (Wah Kheong 2017), and 240 mg of silybin as the phosphatidylcholine complex twice daily for 7 days (Buzzelli 1993). The regimens below are what practitioners describe, reported here as information.

Pre-DAA hepatocellular support (hepatitis C virus awaiting treatment):
Described regimen: standard silymarin 420 mg/day in three divided doses, or the phosphatidylcholine complex 240-360 mg/day, until DAA therapy starts. The stated goal is modest symptom and alanine aminotransferase improvement, with no expectation of viral effect.

Concurrent with DAA therapy:
Described regimen: standard silymarin 280-420 mg/day. No documented benefit on cure rates, no documented harm. Practitioners describe stopping it if unexpected liver test changes appear during the DAA course.

Post-DAA cure with residual cirrhosis or persistent alanine aminotransferase elevation:
Described regimen: standard silymarin 420 mg/day or the phosphatidylcholine complex 240-360 mg/day, indefinite duration, with periodic checks of alanine aminotransferase, aspartate aminotransferase, and synthetic function (albumin, international normalized ratio (INR), bilirubin), alongside lifestyle changes (no alcohol, non-alcoholic fatty liver disease management if metabolic syndrome is present).

Chronic hepatitis B virus (during nucleoside analog therapy):
Described regimen: standard silymarin 420 mg/day as adjunct. It does not replace entecavir or tenofovir.

Highest-dose regimens described (non-alcoholic steatohepatitis or severe chronic disease):
The phosphatidylcholine complex 240 mg three times daily (720 mg/day total), or equivalent high-dose standard silymarin 700 mg twice daily. Practitioners sometimes combine it with N-acetylcysteine (NAC) 600 mg twice daily, alpha-lipoic acid 300-600 mg/day, selenium 200 µg/day, and vitamin E 400-800 international units (IU)/day for a full integrated hepatoprotective protocol.

How it is usually described as being taken:
• With a meal containing some fat, which is said to improve absorption
• Apart from high-fiber meals
• Spaced through the day (every 6-8 hours), given the short serum half-life
• With a bedtime dose as one of the three daily doses, in some accounts

Back to Table of Contents

Symptom and Quality-of-Life Effects

The endpoints where milk thistle does show consistent (if modest) benefit in chronic hepatitis are not the virologic or histologic endpoints but the symptomatic ones. Chronic hepatitis C virus and hepatitis B virus patients commonly experience fatigue, right-upper-quadrant discomfort, low-grade nausea, brain fog, and depressive symptoms — collectively sometimes called "hepatitis C virus-associated extrahepatic syndrome." Several observational studies and pilot trials report improvement in these symptoms with milk thistle.

The Hepatitis Quality of Life Questionnaire (HQLQ), Chronic Liver Disease Questionnaire (CLDQ), and Short-Form 36 (SF-36) have all been used to assess this dimension. Results are mixed but tend to favor silymarin for fatigue and general well-being scores at modest magnitudes (typically 3-8 points on 0-100 scales). The 2012 SyNCH trial did not find significant quality-of-life differences, but the trial population was interferon-failed (already a population with longstanding symptomatic disease) and the 24-week duration may have been too short for subtle quality-of-life changes.

In the HALT-C data, 17% of 1,145 people with advanced hepatitis C were using silymarin at baseline. After adjusting for age, race, education, alcohol, exercise, body mass index and smoking, users still reported less fatigue, nausea, liver pain, poor appetite and muscle and joint pain, and better general health. Their alanine aminotransferase and virus levels were the same as nonusers', and the authors note that use was self-motivated and uncontrolled.

For hepatitis C virus patients who report fatigue and general hepatic discomfort, practitioners describe a 3-month course of standard silymarin 420 mg/day, continued if the person feels better and stopped if not.

Back to Table of Contents

Cautions and Antiviral Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Fried MW et al. (2012). Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 308(3):274-82. — PubMed PMID: 22797645
  2. Seeff LB et al. (2008). Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 47(2):605-12. — PubMed PMID: 18157835
  3. Ferenci P et al. (2008). Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135(5):1561-7. — PubMed PMID: 18771667
  4. Polyak SJ, Ferenci P, Pawlotsky JM (2013). Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology 57(3):1262-71. — PubMed PMID: 23213025
  5. Rambaldi A, Jacobs BP, Gluud C (2007). Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2007(4):CD003620. — PubMed PMID: 17943794
  6. Buzzelli G et al. (1993). A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 31(9):456-60. — PubMed PMID: 8225695
  7. Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P (2011). Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hepatol 54(3):591-2. — PubMed PMID: 21106270
  8. Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, Zhang HY, Li YW (2013). Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis 32(5):657-69. — PubMed PMID: 23247631
  9. Loguercio C, Federico A, Trappoliere M, et al. (2007). The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 52(9):2387-95. — PubMed PMID: 17410454
  10. Wagoner J et al. (2010). Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 51(6):1912-21. — PubMed PMID: 20512985
  11. Mayer KE, Myers RP, Lee SS (2005). Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 12(6):559-67. — PubMed PMID: 16255756
  12. Wah Kheong C, Nik Mustapha NR, Mahadeva S (2017). A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 15(12):1940-1949.e8. — PubMed PMID: 28419855
  13. Esser-Nobis K et al. (2013). Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology 57(3):953-63. — PubMed PMID: 23322644
  14. Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M (2012). Failure of intravenous silibinin monotherapy to prevent hepatitis C genotype 2a liver graft reinfection. Hepat Mon 12(6):411-4. — PubMed PMID: 22879832
  15. Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E (1990). Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 15(4):333-8. — PubMed PMID: 2088770
  16. Bijak M (2017). Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.)-chemistry, bioavailability, and metabolism. Molecules 22(11):1942. — PubMed PMID: 29125572
  17. Huang CH, Wu VC, Wang CL, Wu CL, Huang YT, Chang SH (2024). Silymarin synergizes with antiviral therapy in hepatitis B virus-related liver cirrhosis: a propensity score matching multi-institutional study. Int J Mol Sci 25(6):3088. — PubMed PMID: 38542062
  18. Lewis KC, Barker LK, Jiles RB, Gupta N (2023). Estimated prevalence and awareness of hepatitis C virus infection among US adults: National Health and Nutrition Examination Survey, January 2017-March 2020. Clin Infect Dis 77(10):1413-1415. — PubMed PMID: 37417196
  19. Kawaguchi-Suzuki M, Frye RF, Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Markowitz JS (2014). The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity. Drug Metab Dispos 42(10):1611-6. — PubMed PMID: 25028567
  20. US prescribing information (DailyMed): sofosbuvir and velpatasvir; ledipasvir and sofosbuvir; glecaprevir and pibrentasvir; tacrolimus.

PubMed Topic Searches

  1. PubMed: Silymarin chronic HCV
  2. PubMed: Silymarin chronic HBV
  3. PubMed: IV silibinin HCV
  4. PubMed: Silybin-phosphatidylcholine IdB 1016 bioavailability
  5. PubMed: Silymarin DAA interactions
  6. PubMed: Silymarin post-liver-transplant

Back to Table of Contents

Connections

Back to Table of Contents